TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05796609

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Driving under the influence of alcohol
Description: Participants will drive in three different states (sober, drunk above and below the legal limit) on a designated circuit with a real car on a test track accompanied by a driving instructor. After the initial sober driving session, participants are administered pre-mixed alcoholic beverages (e.g., vodka orange). Participants are expected to achieve a target breath alcohol concentration of 0.35 mg/l (legal limit in Switzerland is 0.25 mg/l breath alcohol concentration) before the second driving session starts. Finally, the third driving session starts when the participants' breath alcohol concentration drops to 0.15 mg/l.~Participants will be blinded to their alcohol levels during the study.~Measurements: Heart rate, respiration rate, blood oxygen saturation, skin conductance, skin temperature, accelerometer, eye movement, radar, facial expression, audio recording, vehicle data, in-cabin gas concentration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Driving under the influence of a placebo
Description: Participants will drive three times at the same intervals as the treatment group on a designated circuit with a real car on a test track accompanied by a driving instructor. After the initial driving session, participants receive placebo beverages (e.g., orange juice with vodka flavor).~Participants are fully blinded.~Measurements: Heart rate, respiration rate, blood oxygen saturation, skin conductance, skin temperature, accelerometer, eye movement, radar, facial expression, audio recording, vehicle data, in-cabin gas concentration
Study: NCT04915807

Intervention type: DRUG
Intervention: Ramucirumab and paclitaxel
Description: Ramucirumab/paclitaxel as a second-line chemotherapy after May 1, 2018, when health insurance coverage for the combination therapy started

Intervention type: DRUG
Intervention: Taxane, irinotecan, or fluoropyrimidine-based single or combined chemotherapy
Description: Taxane, irinotecan , or fluoropyrimidine-based single or combined chemotherapy as a second-line therapy
Study: NCT05722509

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distal Flap Reduction Group
Description: A surgical procedure consisting of a tissue reduction flap distal to the second molar prior to the extraction of the third molar will be performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Only Exodontia Group
Description: Third molar exodontia without associated surgery.
Study: NCT05756764

Intervention type: DRUG
Intervention: Liraglutide
Description: Medication for weight loss
Study: NCT06578715

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Technique
Description: EFT basically involves serial tapping on acupuncture points, no needles are used, there is no invasive procedure, there are affirmation suggestions, it is an easy, painless, simple but effective method that can be done in minutes. It is realized by applying kinetic energy to certain meridians on the head and chest with the fingertips. The points where the tapping is done are the end points of the meridians in the body. They are located symmetrically on both sides of the body. Since these points are close to the skin surface, they are points that are more easily reached than the deeper buried parts of the meridians. While applying pressure with the fingertips, the individual needs to focus on the problem that bothers him/her. Another thing that needs to be done at the same time is for the person to make positive suggestions to himself/herself vocally.
Study: NCT06577584

Intervention type: OTHER
Intervention: Follow-up in the Diabetes Care Trajectory
Description: Being followed-up in the Diabetes Care Trajectory in Belgium

Intervention type: OTHER
Intervention: Follow-up in the Diabetes Convention
Description: Being followed-up in the Diabetes Convention in Belgium
Study: NCT04886960

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amniotic Fluid Injection
Description: Comparison of Standard of Care (Corticosteroid) injection vs. Sterile Processed Amniotic Fluid Injection for Knee Osteoarthritis
Study: NCT05045209

Intervention type: OTHER
Intervention: Virtual rehabilitation
Description: Patient who are assigned to this group will receive virtual rehabilitation
Study: NCT04886960

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Comparison of Standard of Care (Corticosteroid) injection vs. Sterile Processed Amniotic Fluid Injection for Knee Osteoarthritis
Study: NCT06502327

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instructions A
Description: Instructions A are printed visual instructions for health students for inserting a laryngeal mask into neonatal mannequins.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Instructions B
Description: Instructions B are printed visual instructions for health students for inserting a laryngeal mask into neonatal mannequins.
Study: NCT05018481

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hyaluronate
Description: Sodium hyaluronate of molecular weight 35kDa will be given in capsule form to study participants

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo will be given in capsule form to study participants
Study: NCT05337163

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test: Sputum DNA methylation analysis
Description: Diagnostic Test: sputum specimen will be collected by the subject for the detection of Human Multigene Methylation Detection Kit (Fluorescent PCR Method)

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test: Sputum DNA methylation analysis
Description: Diagnostic Test: sputum specimen will be collected by the subject for the detection of Human Multigene Methylation Detection Kit (Fluorescent PCR Method)

Intervention type: PROCEDURE
Intervention: chest CT or pathological examination
Description: Subjects will undergo chest CT or pathological examination.

Intervention type: PROCEDURE
Intervention: chest CT or pathological examination
Description: Subjects will undergo chest CT or pathological examination.
Study: NCT04929951

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Micro Fragmented Adipose Tissue
Description: Harvesting of Micro Fragmented Adipose Tissue with intra-articular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection
Description: Sham harvesting of adipose tissue without intra-articular injection. Intra-articular injection of corticosteroid.
Study: NCT04944706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qishen Yiqi dripping pills 2 bags/time + Qishen Yiqi dripping pills placebo 2 bags/time
Description: Take 3 times a day after meals,24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qishen Yiqi dripping pills 4 bags/time
Description: Take 3 times a day after meals,24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qishen Yiqi dripping pills placebo 4 bags/time
Description: Take 3 times a day after meals,24 weeks
Study: NCT05783102

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Knowledge and Interpersonal Skills to Develop Exemplary Relationships
Description: During this 9-week psychoeducational intervention, participants will complete eight weekly, self-paced lessons that include a short video vignette, written text, a reading quiz, and a reflection exercise. Topics include understanding a dementia diagnosis, communicating with a person you care for about challenging topics, finding a balance between safety concerns and independence, and more. Each lesson takes an estimated 1 hour to complete. Independent KINDER lessons can be completed using a printed or digital copy of the KINDER Workbook. In addition, participants will be asked to participate in three, 1.5-hour group discussion sessions with other caregivers and a facilitator. These sessions will take place over Zoom video conference.
Study: NCT06503692

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DKutting PTA Scoring Balloon Dilatation Catheter
Description: The device consists of a balloon catheter with scoring elements (triangular cross-section) fixed to the surface of the balloon and distributed radially at every 120°. When the balloon is inflated, the expansion force is focused along the scoring elements, causing it to expand under lower balloon pressure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral Balloon Catheter
Description: The device is an over-the-wire (OTW) double-lumen balloon catheter. The balloon is inflated to a known diameter at a specified pressure.
Study: NCT05008835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-044 Dose A
Description: Oral dose of ACP-044 Dose A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-044 Dose B
Description: Oral dose of ACP-044 Dose B

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04616014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORMD-0801 QD
Description: 16 mg, QD, two capsules, 8 mg each.
Study: NCT05124093

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Apnoeic oxygenation
Description: After 2mins 45 seconds of pre-oxygenation with high-flow nasal oxygen at Fio2 1.0 at 50L/min, anaesthesia is induced with 1-1.5mcg/kg remifentanil plus 2-3mg/kg propofol. Propofol (10mg/kg/hr) and remifentanil (0.15mcg/kg/min) infusions administered until study conclusion.~At the onset of apnoea, 1mg/kg rocuronium administered. Jaw thrust performed. High-flow nasal oxygen adjusted to the randomised flow rate. Videolaryngoscopy after 1 minute of apnoea. Airway patency maintained. Tracheal intubation after 4 minutes of apnoea.~Positive pressure ventilation commenced at Spo2 92%. Failure to obtain view of glottis with videolaryngoscope results in withdrawal from the study.~Blood samples obtained from an arterial catheter immediately prior to commencing pre-oxygenation, after 90 and 180 seconds of pre-oxygenation, after each minute of apnoea until six minutes of apnoea, and every two minutes of apnoea thereafter, until Spo2 92%.
Study: NCT04758936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: The doses administered (clonidine 1500mg diluted in NaCl0.9% solution of 50 ml) ranged from 0.01μg/kg/min to 0.03μg/kg/min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The doses administered (dexmedetomidine 200mg diluted in NaCl0.9% 50ml) ranged from 0.4μg/kg/h and can be titrated up to 1.4μg/kg/h.
Study: NCT05124093

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Apnoeic oxygenation
Description: After 2mins 45 seconds of pre-oxygenation with high-flow nasal oxygen at Fio2 1.0 at 50L/min, anaesthesia is induced with 1-1.5mcg/kg remifentanil plus 2-3mg/kg propofol. Propofol (10mg/kg/hr) and remifentanil (0.15mcg/kg/min) infusions administered until study conclusion.~At the onset of apnoea, 1mg/kg rocuronium administered. Jaw thrust performed. High-flow nasal oxygen adjusted to the randomised flow rate. Videolaryngoscopy after 1 minute of apnoea. Airway patency maintained. Tracheal intubation after 4 minutes of apnoea.~Positive pressure ventilation commenced at Spo2 92%. Failure to obtain view of glottis with videolaryngoscope results in withdrawal from the study.~Blood samples obtained from an arterial catheter immediately prior to commencing pre-oxygenation, after 90 and 180 seconds of pre-oxygenation, after each minute of apnoea until six minutes of apnoea, and every two minutes of apnoea thereafter, until Spo2 92%.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Apnoeic oxygenation
Description: After 2mins 45 seconds of pre-oxygenation with high-flow nasal oxygen at Fio2 1.0 at 50L/min, anaesthesia is induced with 1-1.5mcg/kg remifentanil plus 2-3mg/kg propofol. Propofol (10mg/kg/hr) and remifentanil (0.15mcg/kg/min) infusions administered until study conclusion.~At the onset of apnoea, 1mg/kg rocuronium administered. Jaw thrust performed. High-flow nasal oxygen adjusted to the randomised flow rate. Videolaryngoscopy after 1 minute of apnoea. Airway patency maintained. Tracheal intubation after 4 minutes of apnoea.~Positive pressure ventilation commenced at Spo2 92%. Failure to obtain view of glottis with videolaryngoscope results in withdrawal from the study.~Blood samples obtained from an arterial catheter immediately prior to commencing pre-oxygenation, after 90 and 180 seconds of pre-oxygenation, after each minute of apnoea until six minutes of apnoea, and every two minutes of apnoea thereafter, until Spo2 92%.
Study: NCT06209970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA35
Description: All the freshly made HA35 or B-HA samples were diluted to a final concentration of 5 mg/ml. The filter membrane with 220nm pore size was used to filter freshly made HA35 or B-HA injection in order to test its human tissue permeability as \<220nm nino-particle.
Study: NCT05797974

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MyChart enabled virtual weight loss coach
Description: MyChart-enabled virtual coach utilized to aid in preoperative weight loss.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard preoperative weight loss tools
Description: Participants will utilize current standard preoperative weight loss tools.
Study: NCT06519968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4604
Description: AZD4604 will be administered as Dry Powder Inhalation (DPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4604
Description: AZD4604 will be administered as Dry Powder Inhalation (DPI).
Study: NCT05180864

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastrectomy
Description: Open or minimally invasive (sub)total gastrectomy
Study: NCT06220175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Strepsils Intensiv plus Xilocaine spray Arm
Description: After Stepsils Intensiv ingestion, upper GI endoscopy will be performed with a standard diameter tube, with SpO2 non invasive monitoring.
Study: NCT05180864

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastrectomy
Description: Open or minimally invasive (sub)total gastrectomy
Study: NCT06519968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4604
Description: AZD4604 will be administered as Dry Powder Inhalation (DPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4604
Description: AZD4604 will be administered as Dry Powder Inhalation (DPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4604
Description: AZD4604 will be administered as Dry Powder Inhalation (DPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4604
Description: AZD4604 will be administered as Dry Powder Inhalation (DPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4604
Description: AZD4604 will be administered as Dry Powder Inhalation (DPI).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as DPI.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as DPI.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as DPI.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as DPI.
Study: NCT04877041

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intradialytic Cycling
Description: This intervention will consist of intradialytic cycling for 60 minutes 3 times per week for a total of 12 weeks.
Study: NCT06647082

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pediatric Knee Exoskeleton
Description: The current knee exoskeleton is designed specifically for use in children. The device can be operated either bilaterally or unilaterally and is capable of providing 10- 17.4 Nm of torque assistance at the knee joint which is \~60% of the average biological joint torque for an American 15 year old child. It is adjustable in height such that the passive hip joint and powered knee joint can be placed at the correct anatomical location for each child. Thigh and calf cuffs are interchangeable to accommodate varying leg sizes. The device is autonomous, allowing a child to move freely and can even be used outdoors. The device can accommodate for varying lower limb alignment presentations, adjusting to accommodate for varying femoral rotations and varum and valgum alignments at the knee. The device can be worn independently of the visual biofeedback video game, but is intended for participants to use in conjunction with the knee exoskeleton.
Study: NCT05127174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fedratinib Pill
Description: Fedratinib is taken orally once per day, in 100 mg capsules. Fedratinib is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fedratinib Pill
Description: Fedratinib is taken orally once per day, in 100 mg capsules. Fedratinib is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fedratinib Pill
Description: Fedratinib is taken orally once per day, in 100 mg capsules. Fedratinib is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fedratinib Pill
Description: Fedratinib is taken orally once per day, in 100 mg capsules. Fedratinib is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).
Study: NCT04775706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM15912 Active
Description: Randomized, double-blind, placebo-controlled

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomized, double-blind, placebo-controlled
Study: NCT06220175

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xilocaine Spray Arm
Description: After Xilocaine Spray pharyngeal topical anestesia, upper GI endoscopy will be performed with a standard diameter tube, with SpO2 non invasive monitoring.
Study: NCT06654830

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RATT
Description: Robotic-assisted thoracoscopic thymectomy (RATT) will be performed using Da Vinci Robotic Surgical Systems.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VATT
Description: Video-assisted thoracoscopic thymectomy (VATT) was performed using traditional thoracoscopic systems.
Study: NCT06592508

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Virtual Cardiology Program
Description: Ventricle Health Program, which is a remote, virtual, cardiology program that provides heart failure education to patients, monitors for worsening heart failure, and rapidly titrates heart failure medical therapy.
Study: NCT04923893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilta-cel
Description: Cilta-cel infusion will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered intravenously.
Study: NCT06105554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil mesylate
Description: Given by PO
Study: NCT06439381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300mg/600mg of TQH2722 injection
Description: TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.
Study: NCT06605989

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasotracheal intubation
Description: For nasotracheal intubation, the nasal RAE tube will be first inserted through the left nostril for patients in the left nostril side arm. For nasotracheal intubation, the nasal RAE tube will be first inserted through the right nostril for patients in the right nostril side arm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasotracheal intubation
Description: For nasotracheal intubation, the nasal RAE tube will be first inserted through the left nostril for patients in the left nostril side arm. For nasotracheal intubation, the nasal RAE tube will be first inserted through the right nostril for patients in the right nostril side arm.
Study: NCT05243680

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK3511294 (Depemokimab)
Description: GSK3511294 (Depemokimab) will be administered using a pre-filled safety syringe.
Study: NCT06661681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Functional Therapy (CFT)
Description: Cognitive Functional Therapy (CFT) is underpinned by a strong therapeutic alliance, active listening, and motivational interviewing style, covering the following domains:~i) Making sense of pain involves discussing the multidimensional nature of persistent pain, as well as the beliefs, emotions, and behaviors that can perpetuate the vicious cycle of pain and disability.~ii) Exposure with control involves a functional training designed to normalize maladaptive and provocative postural and movement behaviors, where individuals will learn strategies to improve their body awareness and control and modify postures and tasks commonly associated with pain.~iii) Lifestyle change aims to help patients embrace a healthy lifestyle, which will include promoting a gradual increase in physical activity, sleep hygiene counseling, stress management strategies, and social re-engagement.
Study: NCT06250335

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prebiotic Food-Enriched Diet
Description: Given by PO
Study: NCT06661681

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic exercises group
Description: Each session will include stretching exercises targeting the following muscles i) Upper trapezius; ii) Pectoralis minor; iii) Posterior shoulder region, and strengthening exercises targeting the following muscles i) Lower trapezius, ii) Middle trapezius, iii) Serratus punch exercise, iv) Shoulder external rotators, and v) Shoulder internal rotators.
Study: NCT06250335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given by IV